The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve | Zendy

Bülent Haydardedeoğlu | Zendy; Ahmet Zeki Işık | Zendy; Esra Bulgan Kılıçdağ | Zendy

Open Access

The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve

Author(s) -

Bülent Haydardedeoğlu,

Ahmet Zeki Işık,

Esra Bulgan Kılıçdağ

Publication year - 2015

Publication title -

journal of turkish society of obstetric and gynecology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.41

H-Index - 9

eISSN - 1307-7007

pISSN - 1307-699X

DOI - 10.4274/tjod.32656

Subject(s) - medicine , testosterone (patch) , ovarian reserve , pregnancy rate , in vitro fertilisation , dehydroepiandrosterone , luteal phase , transdermal , andrology , assisted reproductive technology , endocrinology , gynecology , pregnancy , hormone , infertility , biology , androgen , pharmacology , genetics

To evaluate to the efficacy of testosterone, dehydroepiandrosterone (DHEA) and growth hormone (GH) supplementations in patients with diminished ovarian reserve (DOR) in assisted reproductive technology (ART) cycles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research